A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease

 Huntington's Disease / Posted 11 months ago

This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in patients with manifest Huntington’s disease (HD).

  • Study start date : 01/01/2019
  • Study end date : 01/03/2022
  • Wales-Based Study Contact : please speak to your clinician
Contact details

Cardiff & Manchester, Birmingham, London, Cambridge, Oxford, Sheffield, Southhampton, Glasgow, AberdeenCardiff global-roche-genentech-trials@gene.com bepartofresearch.nihr.ac.uk

No post found